Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
J Michael Hoopes & Veena R Kumar. (2012) Overview of respiratory syncytial virus disease in young children. Pediatric Health, Medicine and Therapeutics 3, pages 45-50.
Read now
Read now
Parthiv J. Mahadevia, Anthony S. Masaquel, Mark J. Polak & Leonard B. Weiner. (2012) Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. Journal of Medical Economics 15:5, pages 987-996.
Read now
Read now
Leonard B. Weiner, Anthony S. Masaquel, Mark J. Polak & Parthiv J. Mahadevia. (2012) Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics 15:5, pages 997-1018.
Read now
Read now
Nianwen Shi, Liisa Palmer, Bong-Chul Chu, Julie P. Katkin, Caroline B. Hall, Anthony S. Masaquel & Parthiv J. Mahadevia. (2011) Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. Journal of Medical Economics 14:3, pages 335-340.
Read now
Read now
Articles from other publishers (22)
Lingshuang Ren, Lidan Cui, Qianli Wang, Liujiong Gao, Meng Xu, Meng Wang, Qianhui Wu, Jinxin Guo, Li Lin, Yuxia Liang, Nuolan Liu, Yibing Cheng, Juan Yang & Hongjie Yu. (2023) Cost and health‐related quality of life for children hospitalized with respiratory syncytial virus in Central China. Influenza and Other Respiratory Viruses 17:8.
Crossref
Crossref
Mina Suh, Naimisha Movva, Lauren C Bylsma, Jon P Fryzek & Christopher B Nelson. (2022) A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year. The Journal of Infectious Diseases 226:Supplement_2, pages S195-S212.
Crossref
Crossref
Marco Mesa-FriasCarmine RossiBruno EmondBrahim BookhartDavid AndersonSherine DrummondJingru WangPatrick LefebvreLois E LameratoMarie-Hélène Lafeuille. (2022) Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases. Journal of Managed Care & Specialty Pharmacy, pages 1-13.
Crossref
Crossref
Shanshan Zhang, Lily Zainal Akmar, Freddie Bailey, Barbara A Rath, Maren Alchikh, Brunhilde Schweiger, Marilla G Lucero, Leilani T Nillos, Moe H Kyaw, Alexia Kieffer, Sabine Tong, Harry Campbell, Philippe Beutels, Harish Nair, Harish Nair, Harry Campbell, Ting Shi, Shanshan Zhang, You Li, Peter Openshaw, Jadwicha A Wedzicha, Ann R Falsey, Mark Miller, Philippe Beutels, Marina Antillon, Joke Bilcke, Xiao Li, Louis Bont, Andrew Pollard, Eva Molero, Federico Martinon-Torres, Terho Heikkinen, Adam Meijer, Thea Kølsen Fischer, Maarten van den Berge, Carlo Giaquinto, Rafael Mikolajczyk, Judy Hackett, Eskinder Tafesse, Antonio Gonzalez Lopez, Ilse Dieussaert, Nadia Dermateau, Sonia Stoszek, Scott Gallichan, Alexia Kieffer, Clarisse Demont, Arnaud Cheret, Sandra Gavart, Jeroen Aerssens, Veronique Wyffels, Matthias Cleenewerck, Robert Fuentes, Brian Rosen, Harish Nair, Harry Campbell, Ting Shi, Shanshan Zhang, You Li, Peter Openshaw, Jadwicha A Wedzicha, Ann R Falsey, Mark Miller, Philippe Beutels, Marina Antillon, Joke Bilcke, Xiao Li, Louis Bont, Andrew Pollard, Eva Molero, Federico Martinon-Torres, Terho Heikkinen, Adam Meijer, Thea Kølsen Fischer, Maarten van den Berge, Carlo Giaquinto, Rafael Mikolajczyk, Judy Hackett, Eskinder Tafesse, Antonio Gonzalez Lopez, Ilse Dieussaert, Nadia Dermateau, Sonia Stoszek, Scott Gallichan, Alexia Kieffer, Clarisse Demont, Arnaud Cheret, Sandra Gavart, Jeroen Aerssens, Veronique Wyffels, Matthias Cleenewerck, Robert Fuentes & Brian Rosen. (2020) Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases 222:Supplement_7, pages S680-S687.
Crossref
Crossref
Sebastien Kenmoe, Cyprien Kengne-Nde, Abdou Fatawou Modiyinji, Giuseppina La Rosa & Richard Njouom. (2020) Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies. PLOS ONE 15:2, pages e0229357.
Crossref
Crossref
Gary M. Ginsberg, Eli Somekh & Yechiel Schlesinger. (2018) Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis. Israel Journal of Health Policy Research 7:1.
Crossref
Crossref
Caroline Amand, Sabine Tong, Alexia Kieffer & Moe H. Kyaw. (2018) Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Services Research 18:1.
Crossref
Crossref
Landry Kabego, Serge Balol’Ebwami, Joe Bwija Kasengi, Serge Miyanga, Yvette Lufungulo Bahati, Richard Kambale & Corena de Beer. (2018) Human respiratory syncytial virus: prevalence, viral co-infections and risk factors for lower respiratory tract infections in children under 5 years of age at a general hospital in the Democratic Republic of Congo. Journal of Medical Microbiology 67:4, pages 514-522.
Crossref
Crossref
Evan J. Anderson, Xavier Carbonell-Estrany, Maarten Blanken, Marcello Lanari, Margaret Sheridan-Pereira, Barry Rodgers-Gray, John Fullarton, Elisabeth Rouffiac, Pamela Vo, Gerard Notario, Fiona Campbell & Bosco Paes. (2017) Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Pediatric Infectious Disease Journal 36:2, pages 160-167.
Crossref
Crossref
Pablo F. Céspedes, Emma Rey-Jurado, Janyra A. Espinoza, Claudia A. Rivera, Gisela Canedo-Marroquín, Susan M. Bueno & Alexis M. Kalergis. (2017) A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Vaccine 35:5, pages 757-766.
Crossref
Crossref
Scott A. Lorch & Shawna Calhoun. 2017. Respiratory Outcomes in Preterm Infants. Respiratory Outcomes in Preterm Infants
119
137
.
K K McLaurin, A M Farr, S W Wade, D R Diakun & D L Stewart. (2016) Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. Journal of Perinatology 36:11, pages 990-996.
Crossref
Crossref
Koos Korsten, Maarten O. Blanken, Elisabeth E. Nibbelke, Karel G.M. Moons & Louis Bont. (2016) Prediction model of RSV-hospitalization in late preterm infants: An update and validation study. Early Human Development 95, pages 35-40.
Crossref
Crossref
Kimmie K. McLaurin, Archana Chatterjee & Doris Makari. (2015) Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes. Infectious Diseases and Therapy 4:4, pages 503-511.
Crossref
Crossref
Alison M. Helfrich, Cade M. Nylund, Matthew D. Eberly, Matilda B. Eide & David R. Stagliano. (2015) Healthy Late-preterm infants born 33–36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Human Development 91:9, pages 541-546.
Crossref
Crossref
G. J. HUGHES, A. J. VAN HOEK, S. SRISKANDAN & T. L. LAMAGNI. (2014) The cost of hospital care for management of invasive group A streptococcal infections in England. Epidemiology and Infection 143:8, pages 1719-1730.
Crossref
Crossref
Eric A. F. Simões, Christopher S. Ambrose, Xionghua Wu & Evan J. Anderson. (2015) Intensive Care Unit Admission Rates for Respiratory Syncytial Virus Infection as a Function of Age in Preterm Infants Born at 32–35-week Gestation and Not Receiving Immunoprophylaxis. Pediatric Infectious Disease Journal 34:3, pages 331.
Crossref
Crossref
Christopher S. Ambrose, Evan J. Anderson, Eric A. F. Simões, Xionghua Wu, Hanaa Elhefni, C. Lucy Park, Frangiscos Sifakis & Jessie R. Groothuis. (2014) Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis. Pediatric Infectious Disease Journal 33:6, pages 576-582.
Crossref
Crossref
Tao Zhang, Qiuli Zhu, Xuelan Zhang, Yunfang Ding, Mark Steinhoff, Steven Black & Genming Zhao. (2014) Clinical Characteristics and Direct Medical Cost of Respiratory Syncytial Virus Infection in Children Hospitalized in Suzhou, China. Pediatric Infectious Disease Journal 33:4, pages 337-341.
Crossref
Crossref
Ieda Aparecida Correa Bueno, Adriana Gut Lopes Riccetto, André Moreno Morcillo, Clarice Weis Arns & Emílio Carlos Elias Baracat. (2012) Respiratory syncytial virus, infants and intensive therapy. The Brazilian Journal of Infectious Diseases 16:1, pages 86-89.
Crossref
Crossref
Paul A. Checchia, Luba Nalysnyk, Ancilla W. Fernandes, Parthiv J. Mahadevia, Yingxin Xu, Kyle Fahrbach & Robert C. WelliverSrSr. (2011) Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis. Pediatric Critical Care Medicine 12:5, pages 580-588.
Crossref
Crossref
Jessie R. Groothuis, J. Michael Hoopes & Val G. Hemming Jessie. (2011) Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Advances in Therapy 28:2, pages 91-109.
Crossref
Crossref